Toripalimab with definitive chemoradiotherapy is a promising treatment strategy for esophageal squamous cell carcinoma. Here, the authors show that ctDNA positivity and bTMB are predictive of response in patients within the EC-CRT-001 phase II trial.
- Baoqing Chen
- Shiliang Liu
- Mian Xi